During the main track presentation, Samsung Biologics' CEO and President John Rim said, "Despite industry challenges, Samsung Biologics is well positioned to kick-start a new phase of growth in ...

INCHEON, South Korea, Jan. 15, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced its latest business ...

INCHEON, South Korea, Jan. 14, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced its latest business ...

During the main track presentation, Samsung Biologics' CEO and President John Rim said, "Despite industry challenges, Samsung Biologics is well positioned to kick-start a new phase of growth in 2025 ...

The company to mark new phase of growth at Bio Campus II with the opening of plant 5 in April - Samsung Biologics to offer ADC services and invest in advanced development and manufacturing ...